Article
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
Antiviral therapy - 1 Jan 2016
Lawitz Eric, Poordad Fred, Hyland Robert H, Wang Jing, Liu Lin, Dvory-Sobol Hadas, Brainard Diana M, McHutchison John G, Gutierrez Julio A
Abstract excerpt
BACKGROUND: Ledipasvir/sofosbuvir ± ribavirin administered for 12 weeks to patients with genotype-1 HCV infection and compensated cirrhosis is effective and well-tolerated. The Phase II TRILOGY-1 and TRILOGY-2 studies investigated whether ledipasvir/sofosbuvir plus the non-nucleotide NS5B inhibitor GS-9669 or the NS3/4A protease inhibitor vedroprevir could reduce treatment duration and/or eliminate the need for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.